Summary
The product DROSTANOLONE-E 200, manufactured by PHARM400, underwent independent testing to verify its composition and potency. The sample, submitted by the Manufacturer Pharmaqo Labs mrp@vitamins.to, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis revealed a concentration of 211.15 mg/ml of Drostanolone Enanthate, exceeding the labeled claim of 200 mg/ml by 5.58%.
The testing process was conducted on 1 February 2024, with the results confirming the presence of Drostanolone Enanthate. However, the sample’s origin and batch number remain unknown, raising questions about consistency and reliability. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Pharmaqo Labs
- Product Name: DROSTANOLONE-E 200
- Active Ingredient: Drostanolone Enanthate
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #38123
- Testing Ordered: 25 January 2024
- Sample Received: 31 January 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Pharmaqo Labs (Manufacturer)
- Analysis Paid For By: Pharmaqo Labs (Manufacturer)
Testing Results
- Specification: 200 mg/ml (as stated on the label)
- Measured Concentration: 211.15 mg/ml
- Accuracy: 105.58% (5.58% above the label claim)
- Variance: 5.58
Verification Details
Verification URL: https://janoshik.com/tests/38123_9L4TQEY87B6Q
Evaluation of Manufacturer-Submitted Testing
This analysis highlights the potency of the tested product but warrants careful evaluation due to its submission by the manufacturer. The lack of batch information and the variance from the labeled claim raise concerns about product consistency and quality control. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that DROSTANOLONE-E 200 is slightly overdosed, with a measured concentration of 211.15 mg/ml. This result reflects strong quality control for this sample, but the lack of batch information and the variance from the label claim underscore the importance of additional testing to ensure consistent dosing and quality across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
